摘要
目的:研究围绝经期睡眠障碍患者治疗中米氮平用药的临床疗效。方法:选取129例围绝经期综合征伴有睡眠障碍患者,按随机数字表法分为对照组(n=64例)和研究组(n=65例)。对照组患者给予谷维素片口服治疗,研究组患者给予米氮平片治疗。对比两组患者观察两组患者治疗前、治疗后4周、治疗后8周的PSQI评分、HAMD-17评分,睡眠临床疗效和抑郁临床疗效,对比治疗前、治疗4周后、治疗8周后脑电图结果及治疗过程中用药不良反应。结果:两组患者治疗前PSQI评分对比无显著性差异(P>0.05),治疗后两组患者4周、8周的PSQI评分均明显低于各自治疗前,且研究组患者评分均明显低于对照组(P<0.05)。对照组患者睡眠疗效总有效率显著低于研究组(χ~2=14.291,P <0.05)。治疗前两组患者HAMD-17评分对比无显著性差异(P>0.05),治疗后两组患者4周、8周的HAMD-17评分均明显低于各自治疗前,且研究组患者评分均明显低于对照组(P<0.05)。对照组患者抑郁疗效总有效率低于研究组(χ~2=12.621,P <0.05)。两组患者治疗前脑电图比较无显著性差异(P>0.05),治疗4周后两组亦无显著性差异(P>0.05),治疗8周后研究组显著好于对照组(P<0.05)。研究组患者不良反应发生率明显高于对照组(χ~2=4.737,P <0.05)。结论:在围绝经期综合征伴有睡眠障碍患者治疗中,米氮平起效快速,可改善睡眠,疗效显著,对脑电图影响较小,有一定不良反应,但需继续增加用药时间进一步观察。
Objective:To study the clinical efficacy of mirtazapine in the treatment of patients with sleep disorders in perimenopausal period.Methods:129 cases of perimenopausal syndrome with sleep disorder were selected and divided into control group(n=64 cases)and research group(n=65 cases)according to random number table method.Patients in the control group were treated with oral oryzanol tablets.Patients in the study group were treated with mirtazapine tablets.The PSQI score,the HAMD-17 score,the clinical efficacy of sleep and the clinical effect of depression were compared between the two groups before treatment,4 weeks after treatment,and 8 weeks after treatment.The EEG results and adverse drug reactions before treatment,4 weeks after treatment and 8 weeks after treatment were compared.Results:There was no significant difference in PSQI scores between the two groups before treatment(P>0.05).After treatment,the PSQI scores at 4 weeks and 8 weeks were significantly lower in the two groups than before treatment.The scores of the study group were significantly lower than the control group.In the group(P<0.05).The total effective rate of sleep efficacy in the control group was lower than in the study group(χ2=14.291,P<0.05).There was no significant difference in HAMD-17 scores between the two groups before treatment(P>0.05).After treatment,HAMD-17 scores at 4 weeks and 8 weeks were significantly lower in the two groups than before treatment.The scores of the study group were Lower than the control group(P<0.05).The total effective rate of depression in the control group was lower than in the study group(χ2=12.621,P<0.05).There was no significant difference in EEG before treatment between the two groups(P>0.05).There was no significant difference between the two groups after 4 weeks of treatment(P>0.05).After 8 weeks of treatment,the study group was significantly better than the control group(P<0.05).The incidence of adverse reactions in the study group was higher than that in the control group(χ2=4.737,P<0.05).Conclusion:In the treatment of perimenopausal syndrome patients with sleep disorders,mirtazapine has a rapid onset,can improve sleep,and has a significant effect.It has little effect on EEG and has some adverse reactions,but it is necessary to continue to increase the medication time to observe further.
作者
孙瑞坦
朴翔宇
蔡鸣
梁倩
SUN Ruitan;PIAO Xiangyu;CAI Ming(Zhongshan Hospital Affiliated to Dalian University,Liaoning Dalian 116001,China)
出处
《河北医学》
CAS
2018年第12期2070-2073,共4页
Hebei Medicine
基金
辽宁省科技攻关计划项目
(编号:20152650137)
